Arcus Biosciences, Inc. Profile Avatar - Palmy Investing

Arcus Biosciences, Inc.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 cl…

Biotechnology
US, Hayward [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Arcus Biosciences, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Arcus Biosciences, Inc. can't present revenue by segment

End of RCUS's Analysis
CIK: 1724521 CUSIP: 03969F109 ISIN: US03969F1093 LEI: - UEI: -
Secondary Listings
RCUS has no secondary listings inside our databases.